For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Cytokinetics Inc (NASDAQ: CYTK) was $43.69 for the day, up 1.87% from the previous closing price of $42.89. In other words, the price has increased by $1.87 from its previous closing price. On the day, 1.72 million shares were traded.
Ratios:
Our analysis of CYTK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on February 07, 2025, initiated with a Buy rating and assigned the stock a target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.
On November 08, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $80.RBC Capital Mkts initiated its Outperform rating on November 08, 2024, with a $80 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’25 when ROBERT HARRINGTON bought 1,350 shares for $42.89 per share.
Malik Fady Ibraham sold 2,000 shares of CYTK for $85,000 on Mar 04 ’25. The EVP Research & Development now owns 116,071 shares after completing the transaction at $42.50 per share. On Mar 04 ’25, another insider, Harrington Robert Arthur, who serves as the Director of the company, sold 900 shares for $42.50 each. As a result, the insider received 38,250 and left with 15,108 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 280.10.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $75.71, while it has fallen to a 52-week low of $40.53. The 50-Day Moving Average of the stock is -7.22%, while the 200-Day Moving Average is calculated to be -16.54%.
Shares Statistics:
A total of 118.21M shares are outstanding, with a floating share count of 115.36M. Insiders hold about 2.57% of the company’s shares, while institutions hold 109.90% stake in the company.
Earnings Estimates
A detailed examination of Cytokinetics Inc (CYTK) is currently in progress, with 12.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.23 and low estimates of -$1.64.
Analysts are recommending an EPS of between -$4.9 and -$6.65 for the fiscal current year, implying an average EPS of -$5.57. EPS for the following year is -$4.7, with 13.0 analysts recommending between -$3.64 and -$6.51.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $90.3M, while the lowest revenue estimate was $4M, resulting in an average revenue estimate of $34.82M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $228.88M in the next fiscal year. The high estimate is $396M and the low estimate is $111.48M.
